JP2023532290A - コロナウイルスに対する免疫応答を誘導するための組成物及び方法 - Google Patents

コロナウイルスに対する免疫応答を誘導するための組成物及び方法 Download PDF

Info

Publication number
JP2023532290A
JP2023532290A JP2022580180A JP2022580180A JP2023532290A JP 2023532290 A JP2023532290 A JP 2023532290A JP 2022580180 A JP2022580180 A JP 2022580180A JP 2022580180 A JP2022580180 A JP 2022580180A JP 2023532290 A JP2023532290 A JP 2023532290A
Authority
JP
Japan
Prior art keywords
coronavirus
cpg
antigen
peptide
spike protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580180A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021263131A5 (https=
JP2023532290A5 (https=
Inventor
マーティン ピー． スタインバック，
ラーキャナ エム． シナッパ，
ピーター シー． デムース，
クリストファー エム． ハック，
リサ マクニール，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elicio Therapeutics Inc
Original Assignee
Elicio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elicio Therapeutics Inc filed Critical Elicio Therapeutics Inc
Publication of JP2023532290A publication Critical patent/JP2023532290A/ja
Publication of JPWO2021263131A5 publication Critical patent/JPWO2021263131A5/ja
Publication of JP2023532290A5 publication Critical patent/JP2023532290A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022580180A 2020-06-26 2021-06-25 コロナウイルスに対する免疫応答を誘導するための組成物及び方法 Pending JP2023532290A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063044773P 2020-06-26 2020-06-26
US63/044,773 2020-06-26
US202063064836P 2020-08-12 2020-08-12
US63/064,836 2020-08-12
US202063124200P 2020-12-11 2020-12-11
US63/124,200 2020-12-11
US202163145200P 2021-02-03 2021-02-03
US63/145,200 2021-02-03
PCT/US2021/039134 WO2021263131A1 (en) 2020-06-26 2021-06-25 Compositions and methods for inducing an immune response against coronavirus

Publications (3)

Publication Number Publication Date
JP2023532290A true JP2023532290A (ja) 2023-07-27
JPWO2021263131A5 JPWO2021263131A5 (https=) 2024-07-08
JP2023532290A5 JP2023532290A5 (https=) 2024-07-08

Family

ID=79281915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580180A Pending JP2023532290A (ja) 2020-06-26 2021-06-25 コロナウイルスに対する免疫応答を誘導するための組成物及び方法

Country Status (9)

Country Link
US (1) US20230263882A1 (https=)
EP (1) EP4171574A4 (https=)
JP (1) JP2023532290A (https=)
KR (1) KR20230044404A (https=)
AU (1) AU2021294342A1 (https=)
BR (1) BR112022026580A2 (https=)
CA (1) CA3183735A1 (https=)
MX (1) MX2023000041A (https=)
WO (1) WO2021263131A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI884296B (zh) * 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CA3170743A1 (en) * 2020-08-31 2022-03-03 Susanne RAUCH Multivalent nucleic acid based coronavirus vaccines
WO2023114570A1 (en) * 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
WO2023159081A2 (en) * 2022-02-15 2023-08-24 Ohio State Innovation Foundation Nanotechnology based intranasal vaccine for covid-19
CN114752631B (zh) * 2022-06-15 2022-09-02 中国人民解放军军事科学院军事医学研究院 Rna及包含其的新型冠状病毒疫苗和制备方法
WO2024226775A2 (en) * 2023-04-26 2024-10-31 Elicio Therapeutics, Inc. Compositions containing polynucleotide and polypeptide amphiphiles and methods of use thereof
WO2025240477A1 (en) * 2024-05-17 2025-11-20 The Regents Of The University Of California Methods and materials for enhancing delivery of nucleic acid to cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006009011A1 (ja) * 2004-07-15 2006-01-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute コロナウイルススパイクｓ１融合蛋白及びその発現ベクター
JP2015514108A (ja) * 2012-04-05 2015-05-18 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
WO2015079952A1 (ja) * 2013-11-29 2015-06-04 テルモ株式会社 アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1629104A4 (en) * 2003-06-04 2006-11-02 Bioleaders Corp CELL SURFACE EXPRESSION VECTOR OF SARS VIRUS ANTIGEN AND TRANSFORMED MICROORGANISMS
DK3758712T3 (da) * 2018-03-02 2025-08-04 Elicio Therapeutics Inc Cpg-amfifiler og anvendelser deraf
JP7438604B2 (ja) * 2020-02-07 2024-02-27 モデルナティエックス インコーポレイテッド ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006009011A1 (ja) * 2004-07-15 2006-01-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute コロナウイルススパイクｓ１融合蛋白及びその発現ベクター
JP2015514108A (ja) * 2012-04-05 2015-05-18 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
WO2015079952A1 (ja) * 2013-11-29 2015-06-04 テルモ株式会社 アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ACS APPL BIO MATER, vol. 3, JPN6025031936, 18 August 2020 (2020-08-18), pages 5633 - 5638, ISSN: 0005656857 *
ADV HEALTHCARE MATER, vol. 3, JPN6025031934, 2014, pages 343 - 348, ISSN: 0005656856 *
J IMMUNOTHER CANCER, vol. Vol.8(Suppl 3), No.479, JPN6025031937, 9 November 2020 (2020-11-09), pages 295 - 296, ISSN: 0005656858 *
SCI ADV, vol. Vol.7, eabe5819, JPN6025031935, 5 February 2021 (2021-02-05), pages 1 - 14, ISSN: 0005656859 *
VACCINES, vol. VOL:8,NR:2, JPN5023008013, 29 March 2020 (2020-03-29), pages 1 - 12, ISSN: 0005656855 *

Also Published As

Publication number Publication date
CA3183735A1 (en) 2021-12-30
EP4171574A1 (en) 2023-05-03
AU2021294342A1 (en) 2023-02-23
MX2023000041A (es) 2023-03-10
EP4171574A4 (en) 2024-10-23
BR112022026580A2 (pt) 2023-01-24
US20230263882A1 (en) 2023-08-24
KR20230044404A (ko) 2023-04-04
WO2021263131A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
JP2023532290A (ja) コロナウイルスに対する免疫応答を誘導するための組成物及び方法
US20220143171A1 (en) Cd40 ligand fusion protein vaccine
US20210317169A1 (en) Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
US8557247B2 (en) Lyophilised antigen composition
US20240148897A1 (en) Composition for in vivo delivery of rna and preperation method therefor
US20030072768A1 (en) Method to enhance an immune response of nucleic acid vaccination
CN116670267A (zh) 流感病毒的四价mRNA疫苗
EP3545972A1 (en) Varicella zoster virus vaccine
JP2014518620A (ja) リポソーム製剤
JP2017513956A (ja) 核酸ワクチン
HU229255B1 (en) Vaccines
TW202222821A (zh) 用於預防及/或治療covid-19之組合物及方法
CN120282795A (zh) Omicron冠状病毒疫苗构建体及其制备和使用方法
TW202502375A (zh) 用於治療披衣菌之組合物
Zeng et al. Novel adjuvant delivery system constructed by alum-emulsion hybrid nanoparticles with TLR9 agonists boosts vaccine immunity
CN120379690A (zh) 基于核酸的通用疫苗和其使用方法
WO2004052395A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
CN121285384A (zh) 用于在痤疮的治疗中使用的组合物
CN116507344A (zh) 用于诱导针对冠状病毒的免疫应答的组合物和方法
JP2025529906A (ja) コロナウイルスに対するワクチン
HK40097857A (zh) 用於诱导针对冠状病毒的免疫应答的组合物和方法
JP2024511959A (ja) ウイルスワクチン用の多糖類アジュバント
CN118695850A (zh) 通用流感疫苗及使用方法
TW202517779A (zh) 牙齦卟啉單胞菌抗原性構築體
TW202506200A (zh) 用於靶向樹突細胞之奈米遞送之方法及組合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260127